The following article is part of conference coverage from Kidney Week 2018 in San Diego hosted by the American Society of Nephrology. Renal & Urology News staff will be reporting live on medical studies conducted by nephrologists and other specialists who are tops in their field in acute kidney injury, chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from Kidney Week 2018.

SAN DIEGO—Patients on hemodialysis (HD) who have serum phosphate levels of 5.5 mg/dL or more for 3 months despite the use of other phosphate binders experience a reduction in their levels after switching to sucroferric oxyhydroxide, according to results from the latest real-world study of the drug presented at the American Society of Nephrology’s Kidney Week 2018 conference.

The study included 3927 HD patients with elevated serum phosphate levels (above 5.5 mg/dL). Of these, 2067, 1381, and 479 patients had serum phosphate levels of 5.6 to 7 mg/dL (group 1), 7.1 to 8.5 mg/dL (group 2), and more than 8.5 mg/dL (group 3), respectively. A majority (84%) had been prescribed other phosphate binders:  sevelamer (37%), calcium acetate (18%), lanthanum carbonate (3%), or switched between binders (26%).

Continue Reading

According to mixed effects linear regression analyses, 42%, 22%, and 8.3% of patients in groups 1, 2, and 3, respectively, experienced a serum phosphate decline to 5.5 mg/dL or less within 2 years of treatment with sucroferric oxyhydroxide, an iron-based binder. In group 3, mean serum phosphate decreased from 9.36 to 7.62 mg/dL.

In groups 1, 2, and 3, pill burden declined from a mean 8.7, 9.7, and 9.9 pills per day at baseline, respectively, to 4.9, 5.3, and 5.4 pills per day at 2 years, respectively.

“The high pill burden of most phosphate binders can make serum phosphorus control not readily achievable,” Stuart M. Sprague, DO, of the NorthShore University HealthSystem in Chicago, told Renal & Urology News. “Data presented in our poster show improvement in serum phosphate concentrations levels with patients taking about 50% fewer phosphate binder pills per day after being switched to sucroferric oxyhydroxide with varying degrees of elevated serum phosphorus at baseline.”

The study was funded by Fresenius Medical Care in Waltham, Massachusetts, which manufactures sucroferric oxyhydroxide (Velphoro).

Visit Renal & Urology News’ conference section for continuous coverage from Kidney Week 2018.

Related Articles


Sprague SM, Parameswaran V, Ficociello L, et al. Changes in serum phosphorus (sP) among patients with hyperphosphatemia (sP >5.5 mg/dL) switched to sucroferric oxyhydroxide for two years. Presented at the American Society of Nephrology’s Kidney Week 2018 conference in San Diego, Oct. 23-28. Poster TH-PO195.